Dublin, Sept. 25, 2017 -- The "China Pharmaceutical Distribution Industry Report, 2017-2021" report has been added to Research and Markets' offering.
The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit RMB2.9784 trillion in 2021 at a growth rate of 10% over the next five years driven by favorable policies and downstream demand.
Western medicine sales dominate the Chinese pharmaceutical distribution market, accounting for 74.4% in 2016; East China and Central South China hold relatively higher percentages, up to 61.1% together in 2016.
By the end of Nov 2016, there were 12,975 pharmaceutical wholesalers nationwide which competed fiercely in a lowly concentrated market. Top3 champions seized only a combined 28.7% share of the market in 2016.
As medical reform policies are implemented and consolidation in pharmaceutical wholesale industry accelerates, the Chinese pharmaceutical distribution market will show trends as follows: 1) pharmaceutical E-commerce will become an important model; 2) pharmaceutical supply chain management will be upgraded; 3) capital market will play a bigger role in integration of enterprises; 4) cross-border integration of pharmaceuticals and E-commerce will continue; 5) stiffer competition will improve market concentration; 6) Wholesale-retail integration will spur industry consolidation.
Key Topics Covered:
1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
2 Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Operating Efficiency and Service Functions Gets Improved Constantly
2.6.3 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.4 Pharmaceutical Supply-chain Management Services Are Upgraded Rapidly
2.6.5 Cross-border Integration of Pharmaceuticals and E-commerce Continues
2.6.6 Stiffer Competition Improves Market Concentration
2.6.7 Growing Trend towards Regionalization
2.6.8 Wholesale-retail Integration Spurs Industry Consolidation
3 Chinese Drug Retail Market
3.1 Market Size
3.2 Quantity
3.3 Top 100 Pharmacy Chains
3.4 Online Pharmacy
3.5 Independent Pharmacy
4 Major Enterprises
- Cachet Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd.
- China Meheco Co., Ltd.
- China National Accord Medicines Corporation Ltd.
- China National Medicines Corporation Ltd.
- China Resources Pharmaceutical Group Limited
- Huadong Medicine Co., Ltd.
- Jointown Pharmaceutical Group Co., Ltd.
- Luyan Pharma Co., Ltd.
- Nanjing Pharmaceutical Co., Ltd.
- Realcan Pharmaceutical Co., Ltd.
- Shanghai No.1 Pharmacy Co., Ltd.
- Shanghai Pharmaceuticals Holding Co., Ltd.
- Zhejiang Int'l Group Co., Ltd.
- Zhejiang Zhenyuan Share Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/gwp2pq/china
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals


Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



